Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04504825 · MORE INFO

Limitations, agreements, and source contact

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) · Source last updated 2026-07-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
clinicaltrials@alexion.com
organization
Alexion Pharmaceuticals, Inc.
phone
1-855-752-2356
title
Alexion Pharmaceuticals, Inc.
Complete source fields
certain Agreement
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
clinicaltrials@alexion.com
organization
Alexion Pharmaceuticals, Inc.
phone
1-855-752-2356
title
Alexion Pharmaceuticals, Inc.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice